· Published by Health Canada · Official notice
This is duplicated text of a letter from Hoffmann-La Roche Limited. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
April 7, 2014
Dear Health Care Professional:
Subject: Association of ZELBORAF® (vemurafenib) Use with Drug Induced Liver Injury (DILI)
Hoffmann-La Roche Limited (Roche Canada), in consultation with Health Canada, would like to inform you of important new safety information regarding the risk of Drug Induced Liver Injury (DILI) reported with ZELBORAF.
ZELBORAF is indicated as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.
Based on Roche’s analysis of liver related adverse events reported with ZELBORAF use, as of September 26, 2013, 63 cases out of an estimated 20,000 patients treated with ZELBORAF were identified as having experienced Drug Induced Liver Injury (DILI) using the clinical chemistry criteria for DILI developed by an international DILI Expert Working Group1, where DILI is defined as any of the following:
There were no reported deaths among the 63 cases of liver injury. There were two severe cases (based on the DILI severity index by the same Expert Working Group), both reported as hepatic failure; the outcome of one case of severe liver injury was reported as completely resolved with ZELBORAF discontinuation while the outcome of the second severe liver injury case is not available at this time.
The Product Monograph for ZELBORAF will be updated by Roche Canada, in collaboration with Health Canada, to include appropriate information regarding the risks of DILI. Once the updates are complete the updated Product Monograph will be available on the Health Canada website and on the Roche Canada website.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of liver injury or other serious or unexpected adverse reactions in patients receiving ZELBORAF should be reported to Roche Canada or Health Canada.
Hoffmann-La Roche Limited
Drug Safety Department
7070 Mississauga Road
Mississauga, Ontario, L5N 5M8
Toll free: 1-888-762-4388
Fax: 905-542-5864
E-mail: mississauga.drug_safety@roche.com
To correct your mailing address or fax number, contact Hoffmann-La Roche Limited.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions or require additional information regarding the use of ZELBORAF, please contact the Drug Information Department at Hoffmann-La Roche Limited at 1-888-762-4388, Monday to Friday, between 8:30 a.m. and 4:30 p.m. (Eastern Standard Time).
original signed by
Lorenzo Biondi,
Vice President, Medical and Regulatory Affairs
Hoffmann-La Roche Limited
Reference:
1 Case Definition and Phenotype Standardization in Drug-Induced Liver Injury, GP Aithal, PB Watkins, RJ Andrade, D Larrey et al., Clin Pharmacol Ther., 89(6):806-15, 2011.